BlossomHill Therapeutics (BLSM) Targets $125M IPO at $15–$17 a Share
As seen on the 24/7 Wall St. homepage on August 3, 2026.
BlossomHill Therapeutics revised its IPO terms, targeting a $125 million raise at $15 to $17 per share as biotech companies line up to go public ahead of potential regulatory headwinds.
Continue ReadingShow less
BlossomHill Therapeutics has revised its IPO terms, now aiming to raise $125 million by pricing shares in the $15 to $17 range. The updated terms signal that the company and its underwriters are calibrating the offering to attract enough demand while leaving room for a post-listing pop — a common balancing act when a deal is repriced before it hits the market.
The timing is deliberate. BlossomHill is among a group of biotech companies rushing to complete public offerings ahead of what the industry expects to be a more challenging regulatory environment. When companies cluster their IPOs this way, it can reflect a shared belief that the window for favorable conditions is open now but may not stay that way.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
For investors watching the IPO, the revised price range is the number to track. Where the final pricing lands within — or outside — the $15 to $17 band will indicate how strong institutional demand proved to be during the roadshow.
Sources
Mentioned: BLSM